Cervical Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cervical cancer at a specific stage (FIGO 2018 stage IB to IVA), where the cancer is one of three particular types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- People whose treatment plan includes a combination of chemotherapy, radiation therapy, and a specific type of internal radiation called brachytherapy.
Who may not be able to join:
- People whose cervical cancer is of a rare type, such as neuroendocrine cancer of the cervix, or other uncommon subtypes not listed above.
- People whose cancer has spread to distant parts of the body and whose treatment plan does not include a full course of radiation therapy to the pelvis and brachytherapy (confirm with trial site).
- People who are receiving radiation therapy after surgery for cervical cancer, or who are being treated for cervical cancer that has come back after previous treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 9930958309
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recording and reporting the prevalent practices of cervical cancer brachytherapy in the management of cervical cancer in FARO member countries and report outcomes in reference to techniques utilised.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.